| Literature DB >> 30452341 |
Abstract
Most genetic testing requires a doctor's prescription. In April 2017, however, the U.S. Food and Drug Administration (FDA) gave genetics company 23andMe the go-ahead to sell DNA tests assessing the user's level of risk for ten health conditions, including Parkinson's disease and late-onset Alzheimer's disease. This was followed nearly a year later by approval to sell tests for three mutations in the genes BRCA1 and BRCA2 linked to increased breast cancer risk. These remain the only FDA-approved direct-to-consumer (DTC) tests for genetic risk of disease.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30452341 DOI: 10.1109/MPUL.2018.2869315
Source DB: PubMed Journal: IEEE Pulse ISSN: 2154-2287 Impact factor: 0.924